29 septiembre 2014
Analysis of more than 8,000 women who participated in the world’s largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab (Herceptin) should remain the standard of care for this cancer, says a researcher.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/fI4m9Ke17r8/140929105136.htm
